Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

INDIANAPOLIS (AP) — INDIANAPOLIS (AP) — Eli Lilly and Co. (LLY) on Thursday reported first-quarter profit of $2.76 billion. The Indianapolis-based company said it had net income of $3.06 per share.

The last couple of quarters have been very favorable for Eli Lilly and Company (NYSE:LLY) and its position in the obesity and adjacent markets. The main competitor Novo Nordisk A/S (NVO ...

With its 2-star rating, we believe Lilly ... The company encounters considerable regulatory and legal risks, including product approvals, patent challenges, and liability lawsuits.

HSBC on Monday double downgraded Eli Lilly and Co. (LLY) stock to ‘Reduce’ from ‘Buy’ and also lowered its price target to ...

Novo Nordisk to sell Wegovy through telehealth firms to cash-paying US customers Novo Nordisk said on Tuesday it was working with telehealth firms Hims & Hers , Ro and LifeMD to sell Wegovy, as it ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other Billionaire Ken Fisher’s healthcare stock picks with massive upside potential.

Building on this, the company declared that Orforglipron would be manufactured in the U.S. Since April 2024, Eli Lilly has become the leader in new prescriptions and is gaining market share in the ...

Chief executive officers from Nvidia Corp., Johnson & Johnson, Eli Lilly & Co., General Electric Co. and SoftBank Group Corp. are among corporate leaders slated to visit the White House on ...